Lucky Iron Fish Home Fortification of Iron
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02341586 |
|
Recruitment Status :
Completed
First Posted : January 19, 2015
Last Update Posted : March 16, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Anemia Anemia, Iron-Deficiency Hemoglobinopathies | Other: Lucky Iron Fish - home fortification system Dietary Supplement: 18 mg elemental iron Other: Nutrition Education | Not Applicable |
Background: Anemia is prevalent in Cambodia, affecting ~44% of women. The causes of anemia are multifactorial. Globally, the most common form is iron deficiency anemia (IDA), which can lead to adverse perinatal health outcomes. In Cambodia, there is evidence that suggests hemoglobinopathies (genetic hemoglobin [Hb] disorders) are prevalent (~50%) and are a major contributor to anemia. In Preah Vihear province, Cambodia, the estimated prevalence of malaria is ~12.3%. Malaria contributes to anemia through a decrease in the production of red blood cells, and an increased destruction of red blood cells.
In Cambodia, iron supplements are recommended to treat anemia, however there is evidence of low compliance among women. The use of cast iron pots has proven to be an effective alternative to prevent and reduce IDA in developing countries. However, cast iron pots are not commonly used in Cambodia because they are expensive, difficult to clean, and heavy. A novel alternative is the Lucky Iron Fish (LIF), which is an iron ingot used during cooking as an in-home fortification system of iron transfer. The LIF ingot is small, lightweight, and easy to clean. Previous research in Cambodia confirmed the acceptance of the LIF to be high, but findings from this study were inconclusive and had several limitations.
Objective: The primary objective of this study is to determine the efficacy of the LIF to increase Hb concentration in Cambodian women of reproductive age.
Methods: A total of 330 women (18-49 y) with mild or moderate anemia (Hb 80-120 g/L) from rural Preah Vihear, Cambodia will be recruited to one of three arms to receive LIF, 18 mg elemental iron, or a placebo. Women with severe anemia will be excluded and referred for treatment. All three groups will receive nutrition education. Monitoring will be conducted monthly to measure compliance.
A trained, Khmer-speaking interviewer will meet with the women to explain the details of the study as per the consent form. Once consent is obtained the trained interviewer will measure hemoglobin status using a hemocue device to confirm eligibility of the study. If eligible, the trained interviewer will then administer the baseline questionnaire in the participant's home.
The questionnaire will collect demographic data, as well as information on current dietary intake, drinking water treatment, knowledge of iron deficiency anemia, knowledge of malaria, and perceptions of supplement use.
Participants will have a venous blood sample taken at 0, 6, and 12 months and analyzed for hemoglobin and multiple biomarkers of iron status (e.g. soluble transferrin receptor, ferritin, and retinol binding protein (RBP)). Ferritin will be corrected for inflammation using measures of alpha-1 acid glycoprotein (AGP, g/L) and C-reactive protein (CRP, mg/L) which are biomarkers of chronic and acute inflammation, respectively.
Genotyping will be conducted to determine the prevalence of hemoglobinopathies among women. The prevalence of malaria in this cohort will be determined using rapid diagnostic test kits for P. Falciparum, and P. Vivax at baseline, midline, and endline.
Potential Significance: The LIF has the potential to be a low cost, effective and simple-to-use product to prevent and reduce iron deficiency anemia in Cambodia.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 340 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Prevention |
| Official Title: | A Randomized Control Trial of the Lucky Iron Fish to Improve Hemoglobin Concentration in Women in Preah Vihear, Cambodia |
| Study Start Date : | April 2015 |
| Actual Primary Completion Date : | May 2016 |
| Actual Study Completion Date : | May 2016 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Lucky Iron Fish
This group will receive a Lucky Iron Fish to use during cooking.
|
Other: Lucky Iron Fish - home fortification system
The Lucky Iron Fish (LIF) is an ingot used during cooking as an in-home fortification system of iron. The LIF works on the same principle as cast iron pots and pans by increasing dietary intake of iron but is small and lightweight. The LIF was designed in collaboration with village elders and community members to ensure it would be accepted in Cambodia. The iron ingot resembles a local fish believed to be lucky among villages in Cambodia, contributing to the acceptability of the ingot. |
|
Active Comparator: 18 mg iron
This group will receive a daily oral iron supplement.
|
Dietary Supplement: 18 mg elemental iron
This dose of iron is the recommend dietary allowance (RDA) for iron for this cohort. Women will receive one-on-one instructions on how best to consume their tablet (for example, with food). |
|
Control group
This group will receive nutrition education
|
Other: Nutrition Education
This group will receive education containing key messages around anemia, malaria, iron intake, and dietary diversity. |
- hemoglobin concentration at endline [ Time Frame: 12 months ]
- Change in ferritin concentration [ Time Frame: Baseline (t=0), midline (t=6 months), and endline (t=12 months) ]Ferritin is a biomarker of iron status. Ferritin will be corrected with measures using measures of alpha-1 acid glycoprotein and C-reactive protein.
- Number of women in Preah Vihear, Cambodia with a genetic hemoglobin disorder [ Time Frame: Midline (t=6 months) ]
- How the prevalence of malaria changes in women living in Preah Vihear Cambodia over one year [ Time Frame: Baseline (t=0), midline (t=6 months), and endline (t=12 months) ]
- Change in soluble transferrin receptor (sTfR) concentration [ Time Frame: Baseline (t=0), midline (t=6 months), and endline (t=12 months) ]sTfR is a biomarker of iron status
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 49 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Mild or Moderate Anemia [Hb 80-119]
- Willing to provide a fingerprick sample of blood at baseline
- Willing to provide 10 mL of venous blood at 0, 6 & 12 months
- Not planning on moving in the next 12 months
- Not participating in any other nutrition intervention
- Be able to provide written and information consent
Exclusion Criteria:
- Be ill or taking any medications [Hb < 80]
- Have normal Hb status [Hb > 120]
- Currently consuming or planning to consume Fe supplements in the next 12 months
- Pregnant (based on self report)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02341586
| Cambodia | |
| Rovieng Health Centre | |
| Rovieng, Preah Vihear, Cambodia | |
| Principal Investigator: | Tim J Green, PhD | University of British Columbia |
| Responsible Party: | Tim Green, Principle Investigator, University of British Columbia |
| ClinicalTrials.gov Identifier: | NCT02341586 |
| Other Study ID Numbers: |
H14-02551 |
| First Posted: | January 19, 2015 Key Record Dates |
| Last Update Posted: | March 16, 2018 |
| Last Verified: | March 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
|
Malaria Cambodia Iron |
Childbearing Age Women Home Fortification |
|
Anemia Anemia, Iron-Deficiency Hemoglobinopathies Hematologic Diseases Anemia, Hypochromic Iron Metabolism Disorders Metabolic Diseases |
Genetic Diseases, Inborn Iron Trace Elements Micronutrients Nutrients Growth Substances Physiological Effects of Drugs |

